Phase 1

June 25, 2007 at 9:52 pm · Filed under phase 1

This list gives a bit more detail about the phase 1 trials in progress. Typically, if there is an announcement of a drug successfully completing a trial, I will move it to the next stage before I see a press release or report saying that a new trial is starting. I assume it will move to the next stage.

[updated August 26, 2012]

Phase I Trials

1. Adrenocorticotrophic Hormone (ACTH, administered as Acthar Gel) (with interferon beta) (University of Southern California)

http://clinicaltrials.gov/show/NCT01049451

2. ARX-424 (pegylated version of interferon beta) (Merck Serono)

http://www.merckserono.com/en/science/pipeline/phase_i/phase_1.html

3. ATX-MS1467 (Apitope Technology / Merck Serono)

http://www.apitope.com/pipeline/index.html

http://www.apitope.com/pipeline/clinical_trials_MS.html

4. AZ01 (Interferon beta 1a – pegylated – bi-weekly or monthly injection) (Allozyne)

www.allozyne.com/wp-content/uploads/2011/10/ALLOZYNE-Announces-Positive-Results-From-Phase-1B-Trial-of-AZ01.pdf

http://www.allozyne.com/pipeline.html

http://www.xconomy.com/seattle/2011/01/10/allozyne-passes-first-clinical-trial-dreams-big-about-a-once-monthly-multiple-sclerosis-drug/?single_page=true

5. BaroFeron (aka NU100) (Nuron Biotech and BaroFold)

http://www.barofold.com/index.php?mact=News,cntnt01,detail,0&cntnt01articleid=2&cntnt01returnid=68

http://www.nuronbiotech.com/central_nerv_system.html

6. BIIB033 (aka Anti-Lingo) (Biogen)

http://www.clinicaltrials.gov/ct2/show/NCT01052506

http://www.biogenidec.com/research_product_pipeline.html

http://english.capital.gr/news.asp?id=896271

7. CS-0777 (Daiichi-Sankyo)

http://www.daiichisankyo.com/rd/pipeline/index.html

http://clinicaltrials.gov/show/NCT00616733

http://www.daiichisankyo.com/ir/archive/mt_pdf/Reference%20Data%282QofFY2010%29_EN.pdf

8. ELND002 (Elan Pharmaceuticals)

http://www.clinicaltrials.gov/ct2/show/NCT01144351

http://www.elan.com/rd/drugs_in_development/product_pipeline.asp

9. Extended Release Formulation of IFNbeta-1a (Rebif) (Merck Serono)

http://www.merckserono.com/en/science/pipeline/phase_i/phase_1.html

10. GBR 500 (Glenmark Pharmaceuticals)

http://www.glenmarkpharma.com/UITemplate/HtmlContainer.aspx?res=P_GLN_GDY_FLIN

http://www.glenmarkpharma.com/GLN_DWL/uploads/MDA%20Q2%20FY11.pdf

11. GSK1223249 (NOGO-A mAb) (GlaxoSmithKline)

http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-2011.pdf

12. GSK2018682 (sphingosine-1 phosphate receptor-1) (GlaxoSmithKline)

http://www.gsk.com/investors/product_pipeline/docs/gsk-pipeline-2011.pdf

13. Lipoic acid (Oregon Health and Science University)

http://www.ohsu.edu/xd/research/centers-institutes/neurology/multiple-sclerosis-center/research/index.cfm

http://www.clinicaltrials.gov/ct2/show/NCT00676156

http://www.clinicaltrials.gov/ct2/show/NCT00997438

http://www.researchcrossroads.org/index.php?view=article&id=50%3Agrant-details&option=com_content&Itemid=64&grant_id=3794469

14. Low Fat Diet (Oregon Health and Science University)

http://www.clinicaltrials.gov/ct2/show/NCT00852722

15. Mesenchymal stem cell transplantation (autologous) (Cleveland Clinic)

http://www.clinicaltrials.gov/ct2/show/NCT00813969

16. Monoclonal antibody against MSRV/HERV-W (GeNeuro)

http://www.geneuro.com/en/technologies/pipeline.php

http://www.geneuro.com/en/technologies/therapeutic/therapeutic_ms_msrv.php

17. MOR103 (MorphoSys)

http://www.morphosys.com/pressrelease/morphosys-initiates-phase-1b-clinical-trial-mor103-patients-multiple-sclerosis

18. NI-0801 (NovImmune)

http://www.novimmune.com/ni-0801-alpha-ip-10.html

http://www.novimmune.com/geneva-switzerland-july13-2009-2.html

19. PDA-001 (aka cenplacel-L) (Celgene Cellular Therapeutics)

http://www.celgene.com/pdfs/product_pipeline.pdf

20. Peptide-coupled, peripheral blood mononuclear cells (Hamburg, Munich, Chicago)

http://multiple-sclerosis-research.blogspot.co.uk/2012/10/ectrims-half-way-to-cure-of-autoimmunity.html

http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=116839&XNSPRACHE_ID=2&XNKONGRESS_ID=126&XNMASKEN_ID=900

21. Prolactin (aka NTx-488) (Stem Cell Therapeutics / University of Calgary)

http://www.stemcellnetwork.ca/index.php?mact=News,cntnt01,detail,0&cntnt01articleid=54&cntnt01detailtemplate=detail_currentProjects&cntnt01returnid=73&hl=eng

http://www.stemcellthera.com/Technology.aspx?section=488

http://cnrp.marketwire.com/cnrp_files/20080707-707sss.pdf

http://cnrp.marketwire.com/cnrp_files/20090409-409SSS1.pdf

22. RGN-352 (RegeneRx)

http://www.regenerx.com/wt/page/clinical_trials

http://www.regenerx.com/wt/page/myocardial_infarction

23. RPC1063 (Receptos)

http://www.receptos.com/clinical-pipeline-at-receptos.php

http://www.receptos.com/clinical-development-RPC1063.php

http://www.businesswire.com/news/home/20110127005431/en/Receptos-Initiates-Clinical-Trials-S1P1-Agonist-Program

24. ShK-186 (Kineta)

http://www.pipelinereview.com/index.php/2012082148695/Small-Molecules/Kineta-Announces-Regulatory-Clearance-to-Initiate-a-Phase-1-Clinical-Trial-for-ShK-186.html

http://www.fiercebiotech.com/story/kineta-uses-unorthodox-strategy-push-autoimmune-drug-clinic/2012-08-21

25. TK54 (LTKfarma)

http://www.ltkfarma.com/index.php?page=22

http://www.genopole.org/media/pdf/eng/annuaire/entreprises/ltk-farma-en.pdf

http://www.prnewswire.co.uk/cgi/news/release?id=174816

26. Valomaciclovir (EPB-348) (Epiphany Biosciences)

http://www.epiphanybio.com/news/2009/Press_Release_24MAR09.pdf

27. XP23829 (XenoPort)

http://phx.corporate-ir.net/phoenix.zhtml?c=187883&p=irol-newsArticle&ID=1717405&highlight=

Permalink